IL2 (Interleukin 2)

News alerts, weekly reports and conference planners

Entrez ID:

IL2-L	Follicular Lymphoma	IL2-L	Follicular Lymphoma	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3
IL2 elevation	Solid Tumor	IL2 elevation	Solid Tumor	everolimus + lenalidomide Sensitive: C3 – Early Trials everolimus + lenalidomide Sensitive : C3	everolimus + lenalidomide Sensitive: C3 – Early Trials everolimus + lenalidomide Sensitive : C3
IL2 elevation	Small Cell Lung Cancer	IL2 elevation	Small Cell Lung Cancer	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
IL2 expression	Gastric Cancer	IL2 expression	Gastric Cancer	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3
IL2 elevation	Mantle Cell Lymphoma	IL2 elevation	Mantle Cell Lymphoma	TG-1701 Sensitive: D – Preclinical TG-1701 Sensitive : D	TG-1701 Sensitive: D – Preclinical TG-1701 Sensitive : D
IL2 elevation	Mantle Cell Lymphoma	IL2 elevation	Mantle Cell Lymphoma	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D	umbralisib + ublituximab-xiiy + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab-xiiy + TG-1701 Sensitive : D

Associations(6)